The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.90
Bid: 1.80
Ask: 2.00
Change: 0.375 (24.59%)
Spread: 0.20 (11.111%)
Open: 1.525
High: 1.90
Low: 1.90
Prev. Close: 1.525
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) - Shield Therapeutics Plc

25 May 2023 12:00

RNS Number : 6702A
Peel Hunt LLP
25 May 2023
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Peel Hunt LLP

(b) Name of offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Shield Therapeutics Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Shield Therapeutics Plc

(d) Date dealing undertaken:

24 May 2023

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

 

N/A

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

Ordinary Shares

Purchase

23,255

6.80 GBx

6.80 GBx

Ordinary Shares

Sale

132,498

6.92 GBx

6.89 GBx

 

 (b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

 

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

Date of disclosure:

25 May 2023

 

Contact name:

Alexandra Forner

Telephone number:

0207 847 4740

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FERBGGDUUBDDGXU
Date   Source Headline
31st Mar 20213:01 pmRNSTotal Voting Rights Update
31st Mar 20213:00 pmRNSBlock Listing 6 Monthly Return
30th Mar 20217:00 amRNSInvestor presentation
26th Mar 20217:00 amRNSStudy demonstrates effectiveness of ferric maltol
24th Mar 20215:40 pmRNSBlock Listing Application
23rd Mar 20215:53 pmRNSHolding(s) in Company
23rd Mar 202112:23 pmRNSHolding(s) in Company
22nd Mar 20217:00 amRNSShield appoints new Chief Financial Officer
18th Mar 20212:02 pmRNSResult of General Meeting & Open Offer
15th Mar 20215:21 pmRNSHolding(s) in Company
9th Mar 20217:00 amRNSAustralia's TGA approves Feraccru
5th Mar 20214:54 pmRNSPDMR Transaction Notification
4th Mar 20216:17 pmRNSPDMR/PCA Transaction Notification
3rd Mar 20211:40 pmRNSInvestor Presentation
1st Mar 20217:00 amRNSPublication of Circular and Notice of GM
26th Feb 20214:09 pmRNSSuccessful completion of £25 million Fundraise
26th Feb 202112:30 pmRNSTotal Voting Rights Update
26th Feb 202111:05 amRNSSecond Price Monitoring Extn
26th Feb 202111:00 amRNSPrice Monitoring Extension
26th Feb 20219:30 amRNSPlacing and Subscription to raise up to £25m
19th Feb 202111:05 amRNSSecond Price Monitoring Extn
19th Feb 202111:00 amRNSPrice Monitoring Extension
2nd Feb 20218:00 amEQSEdison Investment Research Limited: Shield Therapeutics (STX): Beefing up for the US opportunity
29th Jan 20212:38 pmRNSShareholder loan facilities
29th Jan 20217:00 amRNSTotal Voting Rights Update
21st Jan 20215:41 pmRNSDirector/PDMR Shareholding
19th Jan 20212:20 pmRNSDirector/PDMR Shareholding
15th Jan 202110:00 amRNSInvestor presentation
15th Jan 20217:00 amRNSBusiness and trading update
14th Jan 202111:05 amRNSSecond Price Monitoring Extn
14th Jan 202111:00 amRNSPrice Monitoring Extension
6th Jan 20217:15 amEQSHardman & Co Research: Shield Therapeutics (STX): Reassessing the US opportunity
31st Dec 20207:00 amRNSTotal Voting Rights Update
22nd Dec 202010:06 amRNSHolding(s) in Company
21st Dec 20207:00 amRNSInvestor Presentation
18th Dec 20205:21 pmRNSGrant of share options to the CEO
18th Dec 20205:15 pmRNSPDMR Exercise of Share Options
14th Dec 20207:00 amRNSDirector/PDMR Shareholding
14th Dec 20207:00 amRNSInvestor Presentation
10th Dec 202011:05 amRNSSecond Price Monitoring Extn
10th Dec 202011:00 amRNSPrice Monitoring Extension
10th Dec 20207:00 amRNSUpdate re US partnering discussions
30th Nov 20207:00 amRNSHolding(s) in Company
30th Nov 20207:00 amRNSTotal Voting Rights Update
2nd Nov 20207:00 amRNSTotal Voting Rights Update
19th Oct 20207:00 amRNSWithdrawal of all oppositions by TEVA
30th Sep 20201:21 pmRNSBlock Listing 6 Monthly Return
30th Sep 20201:20 pmRNSTotal Voting Rights Update
18th Sep 20201:30 pmEQSHardman & Co Research: Shield Therapeutics (STX): Optimism over US deal
16th Sep 20207:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.